10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended June 30, 2008

 r TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 333-148719

MEDZED, INC.

(Exact name of small business issuer as specified in its charter)

Nevada (State of incorporation) 26-0641585  (IRS Employer ID Number)

c/o   Daniel R. MacLean

7900 East Union Avenue Suite 1100

Denver Colorado 80237

(Address of principal executive offices)

(303) 217-4556

 (Issuer's telephone number)

________________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No r

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer    r	Accelerated filer                           r
Non-accelerated filer       r	Smaller reporting company         x

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes r No x

As of August 13, 2008, 1,500,000 shares of common stock, par value $0.0001 per share, were outstanding.

TABLE OF CONTENTS

	Page
PART I
Item 1. Financial Statements	3
Item 2. Management’s Discussion and Analysis or Plan of Operation	9
Item 3  Quantitative and Qualitative Disclosures About Market Risk	10
Item 4  Controls and Procedures	10
PART II
Item 1.    Legal Proceedings	11
Item IA. Risk Factors	11
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3.    Defaults Upon Senior Securities	11
Item 4.    Submission of Matters to a Vote of Security Holders	11
Item 5.    Other Information	11
Item 6.    Exhibits	11

MEDZED, INC.

(A Development Stage Company)

FINANCIAL STATEMENTS

June 30, 2008 and December 31, 2007

3

PART I

FINANCIAL INFORMATION

Item 1.                      Financial Statements.

MEDZED, INC.

(A Development Stage Company)

Balance Sheets

ASSETS
	June 30,				December 31,
	2008				2007
	(unaudited)
CURRENT ASSETS
Cash		$	9,123			$	2,779
Total Current Assets			9,123				2,779
TOTAL ASSETS		$	9,123			$	2,779
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable		$	2,575			$	550
Related party payable			21,800				5,550
Total Current Liabilities			24,375				6,100
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock: $0.0001 par value, 50,000,000 shares
authorized, 1,500,000 shares issued and outstanding			150				150
Addiitional paid-in capital			14,850				14,850
Deficit accumulated during the development stage			(30,252	)			(18,321	)
Total Stockholders' Equity (Deficit)			(15,252	)			(3,321	)
TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY (DEFICIT)		$	9,123			$	2,779

The accompanying notes are an integral part of these financial statements.

4

MEDZED, INC.

(A Development Stage Company)

Statements of Operations

(unaudited)

							From Inception
	For the Three			For the Six			on August 3,
	Months Ended			Months Ended			2007 Through
	June 30,			June 30,			June 30,
	2008			2008			2008
REVENUES	$	-		$	-		$	-
EXPENSES
General and administrative		4,447			11,931			30,252
Total Expenses		4,447			11,931			30,252
LOSS FROM OPERATIONS		(4,447	)		(11,931	)		(30,252	)
OTHER EXPENSES
Interest expense		-			-			-
Total Other Expenses		-			-			-
NET LOSS	$	(4,447	)	$	(11,931	)	$	(30,252	)
BASIC LOSS PER SHARE	$	(0.00	)	$	(0.01	)
WEIGHTED AVERAGE SHARES OUTSTANDING		1,500,000			1,500,000

The accompanying notes are an integral part of these financial statements.

5

MEDZED, INC.

(A Development Stage Company)

Statements of Stockholders' Equity (Deficit)

(unaudited)

							Deficit
							Accumulated
					Additional		During the			Total
	Common Stock				Paid-in		Development			Stockholders'
	Shares		Amount		Capital		Stage			Equity
Balance at inception, August 3, 2007		-	$	-	$	-	$	-		$	-
Common stock issued for cash at $0.01
per share		1,500,000		150		14,850		-			15,000
Net loss from inception on August 3,
2007 through December 31, 2007		-		-		-		(18,321	)		(18,321	)
Balance, December 31, 2007		1,500,000		150		14,850		(18,321	)		(3,321	)
Net loss for the six months ended
June 30, 2008		-		-		-		(11,931	)		(11,931	)
Balance, June 30, 2008		1,500,000	$	150	$	14,850	$	(30,252	)	$	(15,252	)

The accompanying notes are an integral part of these financial statements.

6

MEDZED, INC.

(A Development Stage Company)

Statements of Cash Flows

(unaudited)

							From Inception
	For the Three			For the Six			on August 3,
	Months Ended			Months Ended			2007 Through
	June 30,			June 30,			June 30,
	2008			2008			2008
CASH FLOWS FROM
OPERATING ACTIVITIES
Net loss	$	(4,447	)	$	(11,931	)	$	(30,252	)
Adjustments to reconcile net loss to net cash
used by operating activities:
Changes in operating assets and liabilities
Increase (decrease) in accounts payable		1,950			2,025			2,575
Net Cash Provided by
Operating Activities		(2,497	)		(9,906	)		(27,677	)
CASH FLOWS FROM INVESTING ACTIVITIES		-			-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party loans		11,250			16,250			21,800
Common stock issued for cash		-			-			15,000
Net Cash Provided by
Financing Activities		11,250			16,250			36,800
NET DECREASE IN CASH		8,753			6,344			9,123
CASH AT BEGINNING OF PERIOD		370			2,779			-
CASH AT END OF PERIOD	$	9,123		$	9,123		$	9,123
SUPPLIMENTAL DISCLOSURES OF
CASH FLOW INFORMATION
CASH PAID FOR:
Interest	$	-		$	-		$	-
Income Taxes	$	-		$	-		$	-

The accompanying notes are an integral part of these financial statements.

7

NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at June 30, 2008 and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2007 audited financial statements.  The results of operations for the periods ended June 30, 2008 and 2007 are not necessarily indicative of the operating results for the full years.

NOTE 2 - GOING CONCERN

The Company’s financial statements are prepared using generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has had no revenues and has generated losses from operations.

In order to continue as a going concern and achieve a profitable level of operations, the Company will need, among other things, additional capital resources and to develop a consistent source of revenues.  Management’s plans include of investing in and developing all types of businesses related to the medical accounting and management industry.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations.  The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

8

Item 2.                      Management’s Discussion and Analysis or Plan of Operations.

As used in this Form 10-Q, references to the “Medzed,” Company,” “we,” “our” or “us” refer to Medzed, Inc. Unless the context otherwise indicates.

Forward-Looking Statements

The following discussion should be read in conjunction with our financial statements, which are included elsewhere in this Form 10-Q (the “Report”). This Report contains forward-looking statements which relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

For a description of such risks and uncertainties refer to our Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission on February 8, 2008. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Overview

Medzed Inc. was incorporated on August 3, 2007 under the laws of the State of Nevada. We have not generated any revenue to date and are a development stage company. We were established for the purpose of becoming a third party reseller of Medical Office Business Solutions. The Company intends to market and resell Electronic Medical Records (EMR) software, Physician Practice Management (PPM) software, and billing software and related services on behalf of the manufacturers of these products.

Plan of Operation

Over the course of the next three month period we plan to focus our efforts on the development of a comprehensive business and marketing plan to assist us with a successful entry into the medical office business solutions market place. Our current management and sole director have over 20 years of experience in management positions in the healthcare industry both in the United States and Canada and will be able to provide sufficient business planning experience to create and execute an effective business plan.  Over the next twelve months, we intend to commence our marketing efforts, which will be directed towards small to medium size healthcare providers, such as medical offices, clinics and ambulatory clinic space.  Initially the Company will focus on physicians’ offices within Denver, Colorado.

Liquidity and Capital Resources

Our balance sheet as of June 30, 2008 reflects cash in the amount of $9,123. Cash from inception to date has been sufficient to provide the operating capital necessary to operate to date.

Notwithstanding, we anticipate generating losses and therefore we may be unable to continue operations in the future. If we require additional capital, we would have to issue debt or equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

9

 Going Concern Consideration

The Company is a development stage company and has not commenced planned principal operations. The Company had no revenues and incurred a net loss of $11,931 for the six months ended June 30, 2008 and a net loss of $30,232 for the period August 3, 2007 (inception) to June 30, 2008. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

In order to continue as a going concern and achieve a profitable level of operations, the Company will need, among other things, additional capital resources and to develop a consistent source of revenues.  Management’s plans include of investing in and developing all types of businesses related to the medical accounting and management industry.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations.  The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3.         Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.         Controls and Procedures.

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the United States Securities and Exchange Commission. Our principal executive officer and principal financial officer has reviewed the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rules 13(a)-15(e) and 15(d)-15(e)) within the end of the period covered by this Quarterly Report on Form 10-Q and has concluded that the disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported in a timely manner. There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the last day they were evaluated by our principal executive officer and principal financial officer.

Changes in Internal Controls over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during the last quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

10

PART II

OTHER INFORMATION

Item 1.                     Legal Proceedings.

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

Item 1A.                  Risk Factors

Smaller reporting companies are not required to provide the information required by this item.

Item 2.                      Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities

None.

Purchases of equity securities by the issuer and affiliated purchasers

None.

Use of Proceeds

None

Item 3.                      Defaults Upon Senior Securities.

None.

Item 4.                      Submission of Matters to a Vote of Security Holders.

There was no matter submitted to a vote of security holders for the six months ended June 30, 2008.

Item 5.                      Other Information.

None

Item 6.                      Exhibits

Exhibit No.	Description
31.1	Rule 13a-14(a)/15d-14(a) Certifications of Daniel R. MacLean, the President, Chief Executive Officer, Treasurer and Director (Attached Hereto)
32.1	Section 1350 Certifications of Daniel R. MacLean, the President, Chief Executive Officer, Treasurer and Director (Attached Hereto)

11

SIGNATURES

In accordance with to requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                            .

	MEDZED, INC
Dated: August 14, 2008	By:	/s/ Danield R. MacLean
		Name:  Daniel R. MacLean
		Title: President, Chief Executive Officer,Treasurer and Director
		(Principal Executive, Financial andAccounting Officer)

By:	/s/ David C. Loucks
	Name: David C. Loucks
	Title:Secretary

12

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO

SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Daniel R. MacLean, the President, Chief Executive Officer, Treasurer and Director of Medzed, Inc. (the “Company”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2008;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4.  I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the Company and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

	MEDZED, INC.
Date: August 14, 2008	By:	/s/ Daniel R. MacLean
		Name Daniel R. MacLean
		Title President, Chief Executive Officer,Treasurer and Director
		(Principal Executive, Financial &Accounting Officer)

                                                                             

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Daniel R. MacLean, the President, Chief Executive Officer, Treasurer and Director of Medzed, Inc. (the “Company”), certifies, under the standards set forth and solely for the purposes of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2008 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

	MEDZED, INC.
Date: August 14, 2008	By:	/s/ Daniel R. MacLean
		Name Daniel R. MacLean
		Title President, Chief Executive Officer,Treasurer and Director (PrincipalExecutive, Financial and AccountingOfficer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.